A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 52-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF SIMUFILAM 100 MG TABLETS IN SUBJECTS WITH MILD-TOMODERATE ALZHEIMER'S DISEASE
Criteria:-Ages 50-87
-Be able to see and hear with no major issues in order to complete assessments in the office during the study
-Not being a smoker or chewing tobacco for at least 3 years
-Participant must have have a study partner/caregiver (family, friend or paid) who spends frequent and sufficient contact with the participant at least 10 hours or more per week, who can provide accurate information regarding the study subject's cognitive and functional abilities, will be able to attend all study visits and complete all procedures during the study as required
-Participant must not reside in a skilled nursing facility requring 24 hour care, they must live at home, with family or an independent or senior apartment type setting or residence.
-English and/or Spanish speaking participants, study partner/caregivers can participate